With 18 new illnesses, the outbreak has grown to 35 cases in 11 states.
A study yesterday in the American Journal of Infection Control has found that only 62% of reported cases of healthcare facility–onset Clostridium difficile (HO-CDI) at a New York hospital met clinical criteria.
Six people have been hospitalized, including one with a serious kidney condition; no food source has been confirmed.
Illnesses from Salmonella Javiana, Thompson, and Infantis have risen about 50% in 10 years.
Fluoroquinolone resistance in hospital-onset E coli bacteremia rose markedly.
A worrisome finding among resistant Salmonella isolates was the Kentucky serovar, of which more than three-quarters were multidrug resistant.
Allergan, a pharmaceutical company based in Dublin, Ireland, yesterday announced that the US Food and Drug Administration (FDA) has approved an expanded indication for its antibiotic combination drug Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by gram-negative organisms.
CutisPharma today announced that the US Food and Drug Administration (FDA) has approved Firvanq, the company's vancomycin oral solution for treating Clostridium difficile–associated diarrhea (CDAD) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
The US Centers for Disease Control and Prevention (CDC) today said an Escherichia coli outbreak tied to leafy greens appears to be over after 25 cases in 15 states and 1 death.
So far the CDC probe hasn't pointed to a specific food type to guide consumers.
